SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: justaninvestor who wrote (389)6/12/1998 2:06:00 PM
From: drdan   of 5402
 

Hi, everyone. Just got off the phone wth the fda, division of blood product evaluation. I spoke with a lady named Marcy who told me that drugs which are structurally and functionally related to an already apporved drug do not as a fact get quicker approval. However, the process theortically is sped up because
FDA researchers would already have data from the previous testing to go along with the present testing. Now remember that this would only apply if the two drugs were functionally similar. I dont imagine that this info amounts to much until we can speak with Dr.Drees.


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News